Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Newamsterdam Pharma Company N.V. (NAMS)

Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NewAmsterdam Pharma Prices $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants Quiver Quantitative, Inc. - Thu Dec 12, 6:44AM CST

NewAmsterdam Pharma announces $416.5 million public offering of ordinary shares and pre-funded warrants to support cardiovascular treatments.Quiver AI SummaryNewAmsterdam Pharma Company N.V., a clinical...

NAMS : 24.82 (-2.93%)
NewAmsterdam Pharma Reports Positive Phase 3 Results for Obicetrapib in Lowering LDL-C and Reducing Cardiovascular Events Quiver Quantitative, Inc. - Tue Dec 10, 4:18PM CST

NewAmsterdam reports positive Phase 3 results for obicetrapib, showing significant LDL-C reduction and favorable safety profile compared to placebo.Quiver AI SummaryNewAmsterdam Pharma Company has reported...

NAMS : 24.82 (-2.93%)
NewAmsterdam Pharma Grants Inducement Share Options to New Non-Executive Hires Quiver Quantitative, Inc. - Sat Dec 7, 1:22AM CST

NewAmsterdam Pharma grants 79,000 share options to new hires as employment inducement under its 2024 Inducement Plan.Quiver AI SummaryNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical firm...

NAMS : 24.82 (-2.93%)
NewAmsterdam Pharma Reports Significant Efficacy and Safety Results in Phase 3 BROOKLYN Trial of Obicetrapib for Heterozygous Familial Hypercholesterolemia Quiver Quantitative, Inc. - Tue Nov 19, 12:32AM CST

NewAmsterdam Pharma reports significant LDL-C and Lp(a) reductions with obicetrapib in Phase 3 trial, maintaining safety comparable to placebo.Quiver AI SummaryNewAmsterdam Pharma Company announced positive...

NAMS : 24.82 (-2.93%)
Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday Motley Fool - Wed Jun 7, 2023

The company announced a stock sale to help fund operations.

NAMS : 24.82 (-2.93%)
EQT Life Sciences closes Dementia Fund at the hard cap PR Newswire - Wed Mar 29, 2023

The LSP Dementia Fund has held its final close at approximately EUR 260 million, at the hard cap and above its original target fund size of EUR 100 million...

NAMS : 24.82 (-2.93%)

Barchart Exclusives

1 Value Stock to Snag After Earnings Barchart - Thu Dec 12, 9:03AM CST
This value stock has just landed robust Q3 results and trades below its sector median, presenting an attractive entry point for investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot